» Articles » PMID: 19446590

Protection Against an Intranasal Challenge by Vaccines Formulated with Native and Recombinant Preparations of the Chlamydia Trachomatis Major Outer Membrane Protein

Overview
Journal Vaccine
Date 2009 May 19
PMID 19446590
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

To compare the ability of a native and a recombinant preparation of the major outer membrane protein of Chlamydia trachomatis mouse pneumonitis (MoPn; Ct-nMOMP and Ct-rMOMP) to protect against an intranasal (i.n.) challenge, BALB/c mice were vaccinated by the intramuscular (i.m.) and subcutaneous (s.c.) routes using CpG-1826 and Montanide ISA 720 as adjuvants. Animals inoculated i.n. with live elementary bodies (EB) of Chlamydia served as a positive control. Negative control groups were immunized with either Neisseria gonorrhoeae recombinant porin B (Ng-rPorB) or with minimal essential medium (MEM-0). Mice immunized with Ct-rMOMP, Ct-nMOMP and EB developed a strong immune response as shown by high levels of Chlamydia specific antibodies in serum and a strong T-cell lymphoproliferative response. Following the i.n. challenge with 10(4) inclusion forming units (IFU) of C. trachomatis, mice immunized with Ct-nMOMP or Ct-rMOMP lost significantly less weight than the negative control animals immunized with Ng-rPorB or MEM-0 (P<0.05). However, mice vaccinated with the Ct-nMOMP lost less weight than those immunized with the Ct-rMOMP (P<0.05). Mice were euthanized at 10 days following the challenge, their lungs weighed and the number of IFU of Chlamydia determined. Based on the lung weight and number of IFU recovered, significant protection was observed in the groups of mice immunized with both Ct-nMOMP and the Ct-rMOMP (P<0.05). Nevertheless, significantly better protection was achieved with the Ct-nMOMP in comparison with the Ct-rMOMP (P<0.05). In conclusion, vaccination with a preparation of the nMOMP elicited a more robust protection than immunization with rMOMP, suggesting that the conformational structure of MOMP is critical for inducing strong protection.

Citing Articles

CT584 Is Not a Protective Vaccine Antigen against Respiratory Chlamydial Challenge in Mice.

Hoang-Phou S, Pal S, Slepenkin A, Abisoye-Ogunniyun A, Zhang Y, Gilmore S Vaccines (Basel). 2024; 12(10).

PMID: 39460301 PMC: 11512284. DOI: 10.3390/vaccines12101134.


Structural Assessment of Major Outer Membrane Protein (MOMP)-Derived Vaccine Antigens and Immunological Profiling in Mice with Different Genetic Backgrounds.

Roe S, Zhu T, Slepenkin A, Berges A, Fairman J, de la Maza L Vaccines (Basel). 2024; 12(7).

PMID: 39066427 PMC: 11281497. DOI: 10.3390/vaccines12070789.


Advances in vaccine development for Chlamydia trachomatis.

Poston T Pathog Dis. 2024; 82.

PMID: 39043447 PMC: 11338180. DOI: 10.1093/femspd/ftae017.


Safety and efficacy of C. muridarum vaccines adjuvanted with CpG-1826 and four concentrations of Montanide-ISA-720-VG.

Slepenkin A, Pal S, Rasley A, Coleman M, de la Maza L NPJ Vaccines. 2024; 9(1):104.

PMID: 38858418 PMC: 11164897. DOI: 10.1038/s41541-024-00880-6.


Determination of the safety and efficacy of recombinant Chlamydia muridarum MOMP vaccines, formulated with CpG-1826 and 70%, 50%, 30% or 10% concentrations of Montanide ISA-720 VG, to elicit protective immune responses against a C. muridarum....

de la Maza L, Slepenkin A, Pal S, Rasley A, Coleman M Res Sq. 2024; .

PMID: 38168233 PMC: 10760204. DOI: 10.21203/rs.3.rs-3688658/v1.


References
1.
Blake M, Gotschlich E . Purification and partial characterization of the opacity-associated proteins of Neisseria gonorrhoeae. J Exp Med. 1984; 159(2):452-62. PMC: 2187218. DOI: 10.1084/jem.159.2.452. View

2.
Tan T, Herring A, Anderson I, Jones G . Protection of sheep against Chlamydia psittaci infection with a subcellular vaccine containing the major outer membrane protein. Infect Immun. 1990; 58(9):3101-8. PMC: 313617. DOI: 10.1128/iai.58.9.3101-3108.1990. View

3.
Westrom L, Joesoef R, Reynolds G, Hagdu A, THOMPSON S . Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis. 1992; 19(4):185-92. View

4.
GRAYSTON J, Wang S . The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis. 1978; 5(2):73-7. DOI: 10.1097/00007435-197804000-00011. View

5.
Su H, Messer R, Whitmire W, FISCHER E, Portis J, Caldwell H . Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med. 1998; 188(5):809-18. PMC: 2213383. DOI: 10.1084/jem.188.5.809. View